Clinical Trial Update: Biological Predictive Factors of Response to ESA in Low Risk MDS Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating biological predictors of response to erythropoiesis-stimulating agents in low-risk myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• erythropoiesis-stimulating agents

Snippet

Sponsor: Association pour la recherche sur les Affections Malignes en Immunologie Sanguine | Conditions: Myelodysplastic Syndromes | Phase 4 | Status: COMPLETED